Who is sponsoring NCT02273765?

NCT02273765 is sponsored by ANRS, Emerging Infectious Diseases.

What drugs are being tested in NCT02273765?

Interventions in NCT02273765: Tenofovir + lamivudine + raltegravir, Tenofovir + lamivudine + efavirenz.

What condition does NCT02273765 study?

NCT02273765 studies HIV-1 Infection, Tuberculosis.

Is NCT02273765 still recruiting?

NCT02273765 is currently completed. Last updated 31 December 2018.

Last reviewed 2018-12-31 · How we verify

NCT02273765: REFLATE TB2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Completed Phase 3 Last updated 31 December 2018

What this trial tests

Phase 3 trial testing Tenofovir + lamivudine + raltegravir in HIV-1 Infection in 460 participants. Completed in 28 November 2018.

Timeline

11 September 2015

Primary endpoint
28 November 2018

28 November 2018

Quick facts

Lead sponsor	ANRS, Emerging Infectious Diseases
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	460
Start date	11 September 2015
Primary completion	28 November 2018
Estimated completion	28 November 2018
Sites	5 locations across France, Vietnam, Mozambique, Côte d’Ivoire, Brazil

Drugs / interventions tested

Tenofovir + lamivudine + raltegravir — full drug profile →
Tenofovir + lamivudine + efavirenz

Conditions studied

HIV-1 Infection — all drugs for HIV-1 Infection →
Tuberculosis — all drugs for Tuberculosis →

Sponsor

ANRS, Emerging Infectious Diseases — full company profile →

Who can join

18 and older, any sex, with HIV-1 Infection or Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase III trial evaluating raltegravir as an alternative to efavirenz for antiretroviral treatment of HIV-infected patients with tuberculosis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
De Castro N, Marcy O, Chazallon C, Messou E, et al · · 2021 · cited 21× · PMID 33667406 · DOI 10.1016/s1473-3099(20)30869-0
Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis.
De Castro N, Chazallon C, N'takpe JB, Timana I, et al · · 2022 · cited 3× · PMID 36540390 · DOI 10.1093/ofid/ofac628
Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial.
Coelho LE, Chazallon C, Laureillard D, Escada R, et al · · 2024 · cited 2× · PMID 38486816 · DOI 10.1093/ofid/ofae035
Tuberculosis disease characteristics associated with mortality, severe morbidity and unsuccessful treatment in people living with HIV treated for tuberculosis - a secondary analysis of the ANRS 12300 Reflate TB2 trial.
Akpata R, Ntakpe JB, Messou E, De Castro N, et al · · 2025 · PMID 40361016 · DOI 10.1186/s12879-025-10986-4

Verify or expand the search:

Other recruiting trials for HIV-1 Infection

Currently open trials in the same condition.

NCT06660498 — Pomalidomide as an Immune-enhancing Agent for the Control of HIV · Phase 1, PHASE2 · recruiting
NCT06602622 — Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI · Phase 4 · recruiting
NCT05705349 — DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) · Phase 3 · active not recruiting
NCT05631093 — A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Vir · Phase 3 · active not recruiting
NCT05630755 — A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Vir · Phase 3 · active not recruiting

Other ANRS, Emerging Infectious Diseases trials

Trials by the same sponsor.

NCT07098481 — Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy · Phase 4 · not yet recruiting
NCT06913959 — HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM) · not yet recruiting
NCT07113106 — Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers · Phase 1, PHASE2 · recruiting
NCT05222945 — A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Pa · NA · not yet recruiting
NCT06522256 — Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of H · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02273765 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ANRS, Emerging Infectious Diseases
Last refreshed: 31 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02273765.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing